HK Stock Movement | BIOCYTOGEN-B (02315) Surges Over 12% to Record High, Set to List on STAR Market with Antibody Platform Delivering Results

Stock News2025-12-09

BIOCYTOGEN-B (02315) surged more than 12%, reaching a record high of HK$35.86. At press time, the stock was up 12.52% at HK$35.76, with a turnover of HK$116.96 million.

The rally follows the company's announcement that its A-share subsidiary, Biocytogen Pharmaceuticals (Beijing) Co., Ltd., has received approval from the Shanghai Stock Exchange to list on the STAR Market on December 10, 2025.

Analysts at Huafu Securities highlighted that the company's "Ten Thousand Antibodies from One Thousand Mice" platform is beginning to yield results, with antibody licensing driving explosive earnings growth. The report noted BIOCYTOGEN's strong preclinical evaluation capabilities, the accelerating commercialization of its antibody development business, and promising drug pipeline potential, initiating coverage with a "Buy" rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195935013?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 10:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195935013","market":"fut","top_or_hot":-1,"title":"HK Stock Movement | BIOCYTOGEN-B (02315) Surges Over 12% to Record High, Set to List on STAR Market with Antibody Platform Delivering Results","media":"Stock News","content":"<p>BIOCYTOGEN-B (02315) surged more than 12%, reaching a record high of HK$35.86. At press time, the stock was up 12.52% at HK$35.76, with a turnover of HK$116.96 million.</p>\n<p>The rally follows the company's announcement that its A-share subsidiary, Biocytogen Pharmaceuticals (Beijing) Co., Ltd., has received approval from the Shanghai Stock Exchange to list on the STAR Market on December 10, 2025.</p>\n<p>Analysts at Huafu Securities highlighted that the company's \"Ten Thousand Antibodies from One Thousand Mice\" platform is beginning to yield results, with antibody licensing driving explosive earnings growth. The report noted BIOCYTOGEN's strong preclinical evaluation capabilities, the accelerating commercialization of its antibody development business, and promising drug pipeline potential, initiating coverage with a \"Buy\" rating.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | BIOCYTOGEN-B (02315) Surges Over 12% to Record High, Set to List on STAR Market with Antibody Platform Delivering Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | BIOCYTOGEN-B (02315) Surges Over 12% to Record High, Set to List on STAR Market with Antibody Platform Delivering Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-09 10:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOCYTOGEN-B (02315) surged more than 12%, reaching a record high of HK$35.86. At press time, the stock was up 12.52% at HK$35.76, with a turnover of HK$116.96 million.</p>\n<p>The rally follows the company's announcement that its A-share subsidiary, Biocytogen Pharmaceuticals (Beijing) Co., Ltd., has received approval from the Shanghai Stock Exchange to list on the STAR Market on December 10, 2025.</p>\n<p>Analysts at Huafu Securities highlighted that the company's \"Ten Thousand Antibodies from One Thousand Mice\" platform is beginning to yield results, with antibody licensing driving explosive earnings growth. The report noted BIOCYTOGEN's strong preclinical evaluation capabilities, the accelerating commercialization of its antibody development business, and promising drug pipeline potential, initiating coverage with a \"Buy\" rating.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1195935013","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195935013","pubTimestamp":1765248807,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BIOCYTOGEN-B (02315) surged more than 12%, reaching a record high of HK$35.86. At press time, the stock was up 12.52% at HK$35.76, with a turnover of HK$116.96 million. The rally follows the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159982":"中证500","399300":"沪深300","688796":"百奥赛图","BK1161":"生物科技","02315":"百奥赛图-B"},"translate_title":"港股动向|百奥赛图-B(02315)涨超12%创历史新高拟科创板上市抗体平台交出业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159982":1,"399300":1,"688796":1,"02315":1},"content_text":"BIOCYTOGEN-B (02315) surged more than 12%, reaching a record high of HK$35.86. At press time, the stock was up 12.52% at HK$35.76, with a turnover of HK$116.96 million.\nThe rally follows the company's announcement that its A-share subsidiary, Biocytogen Pharmaceuticals (Beijing) Co., Ltd., has received approval from the Shanghai Stock Exchange to list on the STAR Market on December 10, 2025.\nAnalysts at Huafu Securities highlighted that the company's \"Ten Thousand Antibodies from One Thousand Mice\" platform is beginning to yield results, with antibody licensing driving explosive earnings growth. The report noted BIOCYTOGEN's strong preclinical evaluation capabilities, the accelerating commercialization of its antibody development business, and promising drug pipeline potential, initiating coverage with a \"Buy\" rating.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195935013","isCrawlerRequest":true}